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ntroduction
ehc¸et’s disease (BD) is a chronic inﬂammatory disease of
nknown etiology.1 The diagnosis is made on the basis of the
ombination of clinical ﬁndings; therefore delay in the diag-
osis is not rare. Sometimes, cardiovascular and pulmonary
nvolvement is seen before making diagnosis of BD. Such man-
festations can be life-threatening and failure to diagnose BD
n such a patient may be very serious.2–4 In this paper, wePlease cite this article in press as: Cinar M, et al. Clinical course of Behcet’s d
of the thrombi with computed tomography angiography: a ﬁve-year follow
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escribe a BD patient diagnosed late with intracardiac, supe-
ior vena cava, and bilateral pulmonary artery thrombi. We
sed computed tomography angiography (CTA) to study the
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icenses/by-nc-nd/4.0/).time course of thrombus development from the time of ini-
tial diagnosis throughout treatment. In this aspect, this is
the ﬁrst report to use CTA to explore the long-term course
of intracardiac, superior vena cava, and bilateral pulmonary
artery thrombi.
Case  reportisease in a patient with delayed diagnosis and radiological follow-up
-up under immunosuppressive treatment. Rev Bras Reumatol. 2016.
nosis, and her ﬁrst complaint was fever, which commenced
in January 2005. Prior to that time, she had suffered from
aphthous lesions, but did not seek medical attention. In April
e under the CC BY-NC-ND license (http://creativecommons.org/
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The clinical course of BD is notably more  severe in males.2  r e v b r a s r e u m a t o
2005, investigations revealed elevated levels of acute phase
reactants including the erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP) level; these were 38 mm/h  and
149 mg/L, respectively. She was admitted to hospital at that
time. On physical examination, multiple oral aphthous ulcers
were detected. Although BD was considered in differential
diagnosis, she was not diagnosed with the disease because
other signs of BD were absent. In fact, she did have a genital
ulcer but, unfortunately, it was not mentioned to the physi-
cian, and the genitalia were not examined. Exhaustive tests
seeking the etiology of the fever were conducted; all of infec-
tious, autoimmune, and malign etiologies were considered.
Echocardiography revealed a cardiac mass 24 mm × 13 mm in
dimensions on the lateral wall of the right ventricular cavity.
This was conﬁrmed by cardiac magnetic resonance imag-
ing (MRI); a soft tissue mass 25 mm × 40 mm  × 40 mm was
evident in the right ventricular cavity. The main features
of this soft tissue mass were its partially moving charac-
ter during systole and diastole, iso-hypointense according
to the myocardial tissue and without contrast enhance-
ment. A cardiac thrombus was initially suspected. A biopsy
was performed, but it was non-diagnostic. Subsequently,
the patient experienced her ﬁrst episodes of pleuritic chest
pain and hemoptysis. Lung ventilation/perfusion scintigraphy
was performed; perfusion loss in multiple segments of both
lungs was evident. Possible foci of thrombosis and causes of
thrombophilia were sought. She was heterozygous for the pro-
thrombin G-A20210 mutation, but neither the V Leiden nor
the MTHFR gene was mutated. The activated partial thrombo-
plastin time, and the levels of lupus anticoagulant, protein C,
protein S, anti-thrombin III, anticardiolipin antibodies, anti-
beta 2-glycoprotein 1 antibodies, and homocysteine were all
normal.
One month later, the right ventricular mass was biopsied
once more  and found to contain only normal heart muscle
ﬁbers and adipose tissue. Hemoptysis re-occurred after biopsy
and persisted for about 1 week. Pulmonary CTA was then per-
formed, and a hypodense ﬁlling defect was evident in the
right ventricle and right pulmonary artery (Fig. 1A1 and B1).
Therefore, anticoagulant therapy (low-molecular weight hep-
arin followed by warfarin) was commenced.
In September 2005, while still on anticoagulant therapy, the
patient was hospitalized with fever, cough, neck and facial
swelling, dyspnea, and palpitations. On physical examination,
she had fever (38.5 ◦C), bilateral jugular venous distention, face
and neck edema, osteofolliculitis, and erythema nodosum
on the right pretibial region. In addition, two genital ulcer
scars and oral aphthae were observed. Human leukocyte anti-
gen B51 test was positive and pathergy test was negative,
so the diagnosis of BD was made. Pulmonary CTA was per-
formed again. The intracardiac thrombus (ICT) noted earlier
remained, but now, dilatations of 2 cm of the ascending and
2.5 cm of the descending branches of the right pulmonary
artery were evident, together with a dilatation of 3 cm of the
descending branch of the left pulmonary artery. All dilatations
were associated with the presence of mural thrombi. Also,
neither the right brachiocephalic vein nor the superior venaPlease cite this article in press as: Cinar M, et al. Clinical course of Behcet’s 
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cava could be visualized because of thrombosis. The clinical
ﬁndings that developed over the 9-month period prior to sub-
sequent treatment are shown in chronological order (Table 1). 1 6;x  x x(x x):xxx–xxx
First, warfarin therapy was discontinued because it was
possible that both a pulmonary arterial aneurysm and arteri-
tis were present. Methylprednisolone (1 g/day for 3 days) was
administered, followed by 1 mg/kg/day of oral prednisolone.
A cyclophosphamide (CYC) pulse of 1 g was started and con-
tinued monthly thereafter. Prednisolone was tapered 4 weeks
later. Symptoms were relieved, and both the CRP level and
the ESR fell to normal ranges. Hemoptysis gradually decreased
and then disappeared.
In November 2005, the patient was re-evaluated by pul-
monary CTA. Thrombi persisted in the intracardiac region, the
superior vena cava (Fig. 1D2) and both pulmonary arteries.
Multiple collateral intercostal veins, which drain the azygos
vein, were serving to drain the upper extremities. A ﬁlling
defect was observed in the descending branch of the left pul-
monary artery (Fig. 1C2). This created a dilatation in the vessel
wall, which was associated with minimal intraluminal con-
trast enhancement. However, this was not considered to be
an aneurysm. In September 2005, the report of a pulmonary
artery aneurysm was reviewed and re-classiﬁed as wall dilata-
tion caused by an intraluminal thrombus.
Eleven months later, while still undergoing monthly CYC
treatment, fever with chills re-occurred associated with an ele-
vated ESR and CRP level (37 mm/h  and 51 mg/L, respectively).
Therefore, interferon-alpha (5 MU three times per week) was
added to therapy and the dose of prednisolone was increased
to 1 mg/kg/day. The patient received a total of 15 g of CYC
over an 18-month period. Interferon therapy was continued for
approximately 11 months. Next, azathioprine 150 mg/day and
acetylsalicylic acid 100 mg/day were commenced. At the time
of writing, the patient remains on this treatment, and the signs
and symptoms previously reported have not re-appeared.
Pulmonary CTA was used to follow-up the thrombi in the
intracardiac region, the pulmonary arteries, and the superior
vena cava. The thrombus in the right ventricle had decreased
in size by 2008 (Fig. 1A2). In 2010, thus 5 years after initial CTA,
the size of the right ventricular thrombus (and the calciﬁc part
thereof) had become further reduced (Fig. 1A3). The thrombus
in the pulmonary artery remained visible on the CTA images in
2008 and 2010. In comparison with the scan performed in 2005,
CTA revealed that the thrombi in the right intermediate lobar
pulmonary artery (Fig. 1B1–B3) and in the left inferior lobar
pulmonary artery (Fig. 1C1–C3) decreased in size over time. In
the CTA scans carried out in 2008 and 2010, thrombosis in the
superior vena cava persisted unchanged in the cranial section
of the azygos drainage (Fig. 1D2–D4). No new thrombi were
noted on follow-up pulmonary CTA. Currently, no clinical or
laboratory evidence indicates the presence of active disease.
Discussion
We report a BD patient with serious complications including
cardiac and vascular involvement. We  describe clinical ﬁnd-
ings prior to clinical diagnosis (thus before treatment) and use
of CTA to follow-up thrombi over 5 years of treatment.disease in a patient with delayed diagnosis and radiological follow-up
-up under immunosuppressive treatment. Rev Bras Reumatol. 2016.
Severe complications such as vascular, neurological and pul-
monary involvement as well as mortality are mostly related
to the male gender.5 Here, life-threatening complications
Please cite this article in press as: Cinar M, et al. Clinical course of Behcet’s disease in a patient with delayed diagnosis and radiological follow-up
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Fig. 1 – Five-year computed tomography angiography (CTA) follow-up of thrombi in the intracardiac region, the superior
vena cava, and both pulmonary arteries.
In 2005 (A1), a CTA scan revealed a large hypodense thrombus in the right ventricle (arrow). In 2008 (A2), the thrombus
decreased in size and was partly calciﬁed, and such shrinkage continued to 2010 (A3).
In 2005 (B1), intraluminal ﬁlling defects were  evident in the right intermediate lobar pulmonary artery (arrow). In 2008 (b2)
and 2010 (b3), a thrombus was evident in this region but became progressively smaller in size.
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Table 1 – Clinical course of Behcet’s disease in a patient with delayed diagnosis and treatment.
Clinical ﬁndings Dec. 2004 Jan. 2005 March 2005 April 2005 May 2005 June 2005 Sep. 2005
Genital ulcer + − − − − − −
Oral aphthous lesiona + + + + + +
Fever + + + + + +
Palpitation + + + + +
Intracardiac thrombus +  + + +
Pleuritic chest pain + + +
Hemoptysis + + +
Cough + + +
Pulmonary artery thrombus + +
Genital ulcer scarsb +
Erythema nodosum +




Face and neck edema +
Jugular venous distention +
Pathergy test − −
HLA B51 +
Superior vena cava thrombus +
Treatment −
– Oral empirical antibiotics +
– IV antibiotics +




LMWH, low molecular weight heparin.
re.a She was suffering from these lesions previously, but those were ra
b Not examined by the physician previously.
developed during diagnostic evaluation were not fatal. It
remains poorly known why females with severe complica-
tions suffer less mortality than males. As a mechanism,
estrogens may suppress pro-inﬂammatory activities of the
vascular endothelium and neutrophils.6 Alternatively, testos-
terone may augment neutrophil functionality, especially in
males.7
Thrombophlebitis and major vessel thrombosis are com-
mon  manifestations of vascular involvement in BD patients,
whereas ICT is extremely rare.1 As in our case, pulmonary and
cardiac complications frequently co-exist.1,8 Fever, hemopty-
sis, dyspnea and cough are common presenting symptoms.8
The frequencies of such complications may be underesti-
mated because the clinical presentation of ICT is nonspeciﬁc
in most patients.
In differential diagnosis of BD with venous thrombo-
sis and pulmonary involvement, Hughes–Stovin SyndromePlease cite this article in press as: Cinar M, et al. Clinical course of Behcet’s 
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(HSS) should be considered. The clinical, radiological, and
histopathological ﬁndings of HSS and BD overlap signiﬁcantly.
HSS is a very rare disorder characterized by thrombophlebitis
In 2005 (C1), hypodense ﬁlling defects were  evident in the left in
thrombus was evident in this region but became progressively sm
In 2005 (D1, D2), thrombosis was evident in the superior vena ca
the VCS via azygos vein (thin white arrow). In 2008 (D3), coronal
cava (thick black arrow). The upper extremities drained to the VC
(thin black arrows). In 2010 (D4), sagittal MIP  CTA imaging condu
little change had occurred. It was very apparent that multiple col
azygos vein also served to drain the upper extremities.and by the presence of multiple pulmonary and/or bronchial
aneurysms. HSS patients usually present with cough, dys-
pnea, fever, chest pain and hemoptysis; these symptoms are
also evident in BD patients. Speciﬁcally, the extent of pul-
monary involvement is often identical in patients with these
diseases. Indeed, HSS has been considered to be a variant of
BD or an incomplete form of the disease. However, ﬁndings
associated speciﬁcally with BD include recurrent genital ulcer-
ation, eye lesions, skin lesions, iritis, arthralgia and a positive
pathergy test; these help to distinguish BD from HSS.9
Thrombophilic factors are expressed in some BD patients
and may contribute to thrombus formation. In our patient,
heterozygous mutation of prothrombin G-A 20210 gene was
detected. Importantly, ICT has been reported to be associated
with deep vein thrombosis and thrombosis of the vena cava
in 50% and 22% of BD cases, respectively.10 We found no evi-
dence of deep vein thrombosis on Doppler ultrasonography.disease in a patient with delayed diagnosis and radiological follow-up
-up under immunosuppressive treatment. Rev Bras Reumatol. 2016.
In patients with ICT associated with BD, the presence of a
pulmonary embolism and/or thrombus should be investigated
even if venous thrombosis cannot be detected.
ferior lobar pulmonary artery. In 2008 (C2) and 2010 (C3), a
aller in size.
va (thick white arrow), and the upper extremities drained to
 CTA imaging revealed thrombosis in the superior vena
S via the collateral circulation and the intercostal veins
cted at the same level as the 2008 CTA scan revealed that
lateral intercostal veins (thin black arrows) draining the
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Association of a thrombotic superior vena cava syndrome
ith ICT is not common in BD patients. However, the inci-
ence of pulmonary embolism and/or thrombus is high in BD
atients with ICT.1,8 The presence of all of ICT, thrombotic
uperior vena cava syndrome, and a pulmonary artery throm-
us/embolism, is extremely rare in BD patients; only ﬁve cases
including the present case) have been described in the litera-
ure. It is sometimes hard to echocardiographically distinguish
etween ICT, vegetations and tumors. However, such distinc-
ions are important, because the treatments and prognoses
iffer. Computed tomography and MRI  might be better meth-
ds for investigating the extension of the involvements, as in
ur case.1,8 Also, although biopsies of the mass in the right
entricular cavity were not diagnostic for our patient, these
id allow us to exclude myxoma, endomyocardial ﬁbrosis, and
ndocarditis.11
Hemoptysis and fever are the most common symptoms of
ulmonary artery involvement in BD.12 Hemoptysis can be
aused by pulmonary aneurysms and/or pulmonary arteritis.
n our case, no aneurysm was detected, and we thus consider
hat the hemoptysis was caused by pulmonary arteritis.
onﬁrmation of the cause of hemoptysis in a BD patient is
ssential to guide the choice of appropriate treatment.11
emoptysis caused us to discontinue anticoagulant
herapy.
Regardless of the site of organ involvement in BD, the aim of
reatment is to prevent irreversible damage that occurs prin-
ipally at early stages of the disease. Thus, early diagnosis is
mportant.11 In our case, diagnosis was made approximately
 months after symptom onset; this delayed initiation of
mmunosuppressive therapy. No consensus has yet emerged
n the management of major vessel disease (with thrombi)
nd ICT in BD patients.13 Various treatment modalities
ncluding surgery, immunosuppressive and anticoagulation
edications, antiplatelet treatments, and thrombolytic ther-
py have been used.10 However, no randomized controlled
tudy has assessed the efﬁcacy of the various therapeutic regi-
ens, and current recommendations are based on only partial
onsensus or observational studies.
Intravenous thrombolytic therapy might be considered for
D patients with ICT and widespread thrombi but without pul-
onary artery aneurysms.8 It is important to emphasize that
f a pulmonary embolism in suspected in a BD patient, neither
nticoagulant nor thrombolytic treatment should commence
efore CTA scanning conﬁrms that aneurysms are absent;
uch treatment would be associated with a high risk of hem-
rrhage if aneurysms were present. The form of pulmonary
rtery occlusion seen in BD patients differs from classic
ulmonary embolisms because the BD occlusions represent
rincipally in situ thrombi complicating underlying vasculitis,
hich may also result in infarction, hemorrhage, hemoptysis,
nd formation of pulmonary artery aneurysms.8,14 As hemop-
ysis was evident, and as it was possible that in situ thrombosis
as present in the pulmonary arteries, we eschewed use of
hrombolytic therapy.
After surgical removal of ICT, thrombus recurs in somePlease cite this article in press as: Cinar M, et al. Clinical course of Behcet’s d
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D patients despite prescription of heparin therapy. This
mphasizes the risk that BD can be worsened by surgery.
herefore, to avoid surgery, immunosuppressive agents
hould be given.10,13,15,16 High-dose methylprednisolone and
1 6;x  x x(x x):xxx–xxx 5
CYC should be the treatment of choice. Interferon alpha
should be given if symptoms do not resolve quickly.11,15,17
We  initially used pulse methylprednisolone and continued
with monthly CYC (15 g in all), and 1 mg/kg/day prednisolone.
Eleven months later, interferon alpha was added because of
recurrence of fever and hemoptysis; this was given for 11
months. We  then continued with azathioprine.
A notable feature of this case report is that complications
did not completely disappear despite immunosuppressive
therapy (Fig. 1A–D). Corticosteroids and immunosuppressive
drugs may nonetheless be very beneﬁcial, particularly if given
at an early stage of development of complications, thus before
irreversible damage develops.10,13
In conclusion, use of the non-invasive CTA technique is
valuable in diagnosis and follow-up of BD patients with intrac-
ardiac and major vascular thrombi. We suggest that BD should
be kept in mind upon differential diagnosis of patients with
ICT and fever. Familiarity with the radiological and clinical
characteristics of BD is essential to ensure accurate early diag-
nosis and prompt treatment.
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